Developing small molecule inhibitors to fight SARS-CoV-2
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2
['FUNDING_R01'] · KANSAS STATE UNIVERSITY · NIH-10670145
This study is working on new medicines that could help stop the COVID-19 virus from making copies of itself, which could lead to better treatments for people who are infected.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | KANSAS STATE UNIVERSITY (nih funded) |
| Locations | 1 site (MANHATTAN, UNITED STATES) |
| Trial ID | NIH-10670145 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small molecule inhibitors that target the 3C-like protease of SARS-CoV-2, the virus responsible for COVID-19. By inhibiting this protease, the research aims to prevent the virus from replicating, which is crucial for developing effective antiviral treatments. The approach involves testing these compounds in cell cultures and animal models to assess their efficacy against coronaviruses. If successful, these inhibitors could provide new therapeutic options for patients infected with COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are infected with SARS-CoV-2 or are at high risk of severe COVID-19 disease.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral drugs for treating COVID-19 and potentially other coronavirus infections.
How similar studies have performed: Previous research has shown success in developing antiviral compounds targeting similar proteases in coronaviruses, indicating a promising avenue for treatment.
Where this research is happening
MANHATTAN, UNITED STATES
- KANSAS STATE UNIVERSITY — MANHATTAN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANG, KYEONG-OK — KANSAS STATE UNIVERSITY
- Study coordinator: CHANG, KYEONG-OK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.